Eiger Biopharmaceuticals Stock News

Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 1.5% above its 52 week low of $4.78, giving the company a market cap of $165M. The stock is currently down 6.0% year-to-date, down 58.2% over the past 12 months, and down 58.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 43.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -422.9% The company's stock price performance over the past 12 months lags the peer average by 313.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 0.6% above its 52 week low of $4.95, giving the company a market cap of $169M. The stock is currently down 4.0% year-to-date, down 60.4% over the past 12 months, and down 57.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 47.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -332.2% The company's stock price performance over the past 12 months lags the peer average by 399.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat

Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 1.0% above its 52 week low of $5.07, giving the company a market cap of $175M. The stock is currently down 57.9% year-to-date, down 50.1% over the past 12 months, and down 52.8% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 14.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 291.2% The company's stock price performance over the past 12 months lags the peer average by 209.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

PALO ALTO, Calif., Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious

State Street Corp raised its position in shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) by 6.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 541,596 shares of the biotechnology companys stock after purchasing an additional 31,230 shares during the quarter. State Street [] The post State Street Corp Purchases 31,230 Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) appeared first on ETF Daily News .

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)’s share price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $7.05 and traded as high as $7.51. Eiger BioPharmaceuticals shares last traded at $6.79, with a volume of 151,146 shares trading hands. Several equities analysts have recently commented on the […]

Eiger BioPharmaceuticals' (EIGR) CEO David Cory on Q3 2021 Results - Earnings Call Transcript

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.07% and 19.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

PALO ALTO, Calif., Sept. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete

Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2021 Results - Earnings Call Transcript

PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete

PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted

PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of target